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Background: To date, the majority of protein-based radiopharmaceuticals have been radiolabelled using non-site-
specific conjugation methods, with little or no control to ensure retained protein function post-labelling. The
incorporation of a hexahistidine sequence (His-tag) in a recombinant protein can be used to site-specifically radiolabel
with 99mTc-tricarbonyl ([99mTc(CO)3]
+). This chemistry has been made accessible via a technetium tricarbonyl kit;
however, reports of radiolabelling efficiencies and specific activities have varied greatly from one protein to another.
Here, we aim to optimise the technetium tricarbonyl radiolabelling method to produce consistently >95% radiolabelling
efficiencies with high specific activities suitable for in vivo imaging.
Methods: Four different recombinant His-tagged proteins (recombinant complement receptor 2 (rCR2) and three single
chain antibodies, α-CD33 scFv, α-VCAM-1 scFv and α-PSMA scFv), were used to study the effect of kit volume, ionic
strength, pH and temperature on radiolabelling of four proteins.
Results: We used 260 and 350 μL [99mTc(CO)3]+ kits enabling us to radiolabel at higher [99mTc(CO)3]+ and protein
concentrations in a smaller volume and thus increase the rate at which maximum labelling efficiency and specific
activity were reached. We also demonstrated that increasing the ionic strength of the reaction medium by increasing
[Na+] from 0.25 to 0.63 M significantly increases the rate at which all four proteins reach a >95% labelling efficiency by
at least fourfold, as compared to the conventional IsoLink® kit (Covidien, Petten, The Netherlands) and 0.25 M [Na+].
Conclusion: We have found optimised kit and protein radiolabelling conditions suitable for the reproducible, fast,
efficient radiolabelling of proteins without the need for post-labelling purification.
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The specificity and affinity of recombinant proteins and
antibodies targeted towards antigens make them highly at-
tractive as a basis for radiopharmaceuticals for molecular
imaging. To retain these key attributes, it is essential not
to compromise the recognition function of the protein
when radiolabelling. This can be achieved using site-
specific labelling methods that exert maximum control
over the number and site of modification(s) to the
molecule, while still maintaining protein function. Such
methodologies should give rise to homogeneous con-
jugates with reproducible chemical and pharmacological* Correspondence: greg.mullen@kcl.ac.uk
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in any medium, provided the original work is pproperties. They must ensure that the conjugation of the
radiochelate is outside of the target binding site or at a
distinct site known not to affect antigen binding. Ideally,
radiolabelling would be achieved rapidly, under mild con-
ditions, to a high specific activity and preferably in a sim-
ple one-pot kit-based method without the need for
subsequent purification steps.
Waibel et al. [1] developed an elegant method that
permits radiolabelling of proteins engineered with se-
quences of additional histidine residues known as His-
tags. The His-tag was originally developed to facilitate
purification of recombinant proteins using metal
chelate-based affinity chromatography. Radiolabelling of
His-tags could be achieved with technetium-99 m
(99mTc) in its stable + I oxidation state in the form of
99mTc-tricarbonyl ([99mTc(CO)3]
+). This organometallicOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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(CO)3(H2O)3]
+ in a one-step reaction by reduction of
the generator-eluted form of 99mTc, sodium pertechne-
tate ([99mTcO4]
−). Histidine has been demonstrated to be
the favoured [99mTc(CO)3]
+-binding ligand among
amino acids and labelling efficiency and stability increase
with increased number of engineered histidines [2]. Dir-
ect labelling of non-His-tag proteins with [99mTc(CO)3]
+
has previously resulted in poor stability and low labelling
efficiency and specific activity, indicating that other po-
tential amino acid side chains donor groups such as
thiol, thioether, carboxylate and amine do not make a
significant contribution in the absence of histidines [3-9].
Modification of the His-tag sequence from HHHHHH to
HEHEHE in order to improve tracer biodistribution also
resulted in reduced labelling efficiency [10,11]. In contrast,
by engineering an additional cysteine seven amino acids
downstream of the His-tag, Tavaré et al. demonstrated an
improvement in labelling efficiency and specific activity
compared to His-tag alone [12] and showed for the first
time that the radiolabelling is indeed site-specific to the
His-tagged region of the protein by carrying out tryptic di-
gest and mass spectrometry on a His-tagged protein la-
belled with [Re(CO)3]
+. The rhenium complex was only
present in His-tag-containing fragments [12]. Further-
more, we recently demonstrated that the engineered cyst-
eine that increases radiolabelling efficiency is also involved
in the coordination of the rhenium tricarbonyl [13]. Sev-
eral variants on labelling conditions have been studied to
optimise the use of [99mTc(CO)3]
+-labelling of His-tagged
proteins, and there is a general agreement in the literature
that labelling at neutral pH, high protein concentration
and high temperature increase the rate of radiolabelling
(see Additional file 1: Table S1) [1,2,12,14-26]. These con-
ditions, however, exclude proteins that are susceptible to
aggregation or loss of function at high temperatures and
concentrations or require particularly high specific activity
[15,23,25]. To make this labelling chemistry readily access-
ible, a kit-based formulation has until recently been dis-
tributed by Mallinckrodt (subsidiary of Covidien, Petten,
The Netherlands) under the trademarked name IsoLink.
Since its introduction, IsoLink has supported the develop-
ment of numerous protein-based imaging tracers. Despite
the intent to provide a practical, simple and versatile radi-
olabelling method, there has been a large variation in la-
belling efficiencies reported in the literature, likely due to
variations in protein/peptide properties and labelling con-
ditions (see Additional file 1: Table S1), and no clinical
trial has been performed to date with proteins labelled
using the tricarbonyl labelling method.
The IsoLink kit comes in a 10-mL glass vial containing
lyophilised reagents and is designed to reduce up to
3.7 GBq of [99mTcO4]
− in a final volume of 1 mL. With
the current composition, to achieve maximum specificactivity (crucial for in vivo imaging), the protein must be
added to this total volume, leading to low protein con-
centration and hence inefficient labelling [12] and high
wastage. Recombinant proteins used in R&D are often
precious, produced in low yield and available in small
quantities and may be difficult to concentrate due to ag-
gregation, precipitation or loss on columns or membranes.
Furthermore, for preclinical work, volumes above 200 μL
are not desirable or feasible for injection into mice (one
tenth of total blood volume). The current kit necessitates
an avoidable and time-consuming protein concentration
step or leads to low specific activity. Thus, while labelling
via the [99mTc(CO)3]
+ method may be one of the most
promising site-specific methods currently available for
recombinant protein tracer development, the IsoLink kit
in its current form is not optimal for routine use in
preclinical research or for future clinical imaging. It
needs to be optimised to achieve reproducible high la-
belling efficiencies (LE) and specific activities (SA) of re-
combinant proteins, without wasting large amounts of
protein and 99mTc.
In this paper, we address how the kit could be further
optimised to increase specific activity and radiolabelling
efficiency of His-tagged proteins, at suitable labelling
rates with reduced wastage of protein and radioactivity.
We used four different His-tagged proteins to study the
effect of various radiolabelling conditions.
Methods
Materials
IsoLink kits (generously provided by Covidien, Petten,
The Netherlands) consisted of lyophilised formulation in
an N2-flushed 10-mL glass vial, containing 8.5 mg so-
dium tartrate Na2C4H4O6, 2.85 mg sodium tetraborate
Na2B4O7, 7.15 mg sodium carbonate Na2CO3 and
4.5 mg sodium boranocarbonate Na2H3BCO2. Kits are
now available from an alternate supplier (Centre of Ra-
diopharmaceutical Research at the Paul Scherrer Insti-
tute in Switzerland) or can be prepared according to
Waibel et al. [1].
His-tagged proteins used in this study were (1) recom-
binant complement receptor 2 (rCR2) (16 kDa) recom-
binant protein [27], (2) α-CD33 scFv (29 kDa) [28], (3)
α-PSMA scFv (27.7 kDa) [29] and (4) α-VCAM-1 scFv
(28.8 kDa) [30]. Protein concentration was measured by
UV spectrometry using a Nanodrop device (Thermo-
Scientific, Loughborough, Leicestershire, LE, UK) and a
molar extinction coefficient of the respective protein de-
termined by ProtParam [31].
Preparation of [99mTc(CO)3]
+
Three methods were used and compared in the produc-
tion of [99mTc(CO)3]
+: a standard method employing an
IsoLink kit according to the manufacturer's instructions
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duced volume of [99mTcO4]
− solution (method 2) and a
new subdivided kit formulation (method 3).
Methods 1 and 2
Up to 2.5 GBq [99mTcO4]
− in 1 mL (method 1) or in 350 to
400 μL (method 2) of saline was added to the kit and heated
for 30 min at 100°C. The vial was then allowed to cool to
room temperature (RT) and the solution neutralised with
145 to 160 μL (methods 1 and 2) of 1 M HCl to pH ap-
proximately 7.5 giving a total volume of 1,145 to 1,160 μL
(method 1) or 495 to 560 μL (method 2), respectively.
Method 3
IsoLink kits were reconstituted in 1 mL ultrapure milliQ
water (Millipore, Billerica, MA, USA), degassed with ni-
trogen and subdivided into aliquots of 260 μL in micro-
centrifuge tubes with rubber ring-sealed screw caps
(Nalgene, Rochester, NY, USA) under anaerobic environ-
ment. Aliquots were snap-frozen in liquid nitrogen,
freeze-dried overnight, then stored at −80°C. Upon use,
kits were allowed to thaw to RT, and up to 1 GBq
[99mTcO4]
−, generator elulate (100 μL) was added and
heated for 30 min at 100°C. The microcentrifuge tube
was then allowed to cool to RT and the solution neutra-
lised with 25 μL of 1 M HCl to pH approximately 7.5
giving a total volume of 125 μL of [99mTc(CO)3]
+.
Quality control
To determine the radiochemical purity of the [99mTc
(CO)3]
+ produced, glass-backed silica gel 60 F254 thin
layer chromatography (TLC) plates (3 cm × 7.5 cm,
Merck™, Darmstadt, Germany) were used with a mobile
phase of 1% HCl in methanol. Plates were analysed with
a gamma ray TLC scanner (Lablogic, South Yorkshire,
UK). Purity was expressed as a ratio of the [99mTc(CO)3]
+
peak integral (Rf = 0.2 − 0.8) to integral of the whole chro-
matogram (including Rf = 0 for




+ radiolabelling of His-tagged recombinant
proteins
To 100 μL of rCR2 (1 mg/mL, 62.5 μM) or α-CD33 scFv
(1 mg/mL, 34.5 μM), or 20 μL of α-PSMA scFv (1 mg/
mL, 36.1 μM) or α-VCAM-1 scFv (1 mg/mL, 34.7 μM) in
PBS (0.14 M [Na+]), a 20-μL solution of [99mTc(CO)3]
+
(prepared according to method 2 above for CD33 scFv,
PSMA scFv and VCAM-1 scFv and method 3 for rCR2)
was added. Each protein was radiolabelled in a final solu-
tion containing low, medium and high concentrations of
Na+: 0.25 M [Na+] (low), 0.44 M [Na+] (medium) and
0.63 M [Na+] (high). The Na+ concentration of the [99mTc
(CO)3]
+ solution was adjusted with NaCl solution before
being added to the protein. The concentration and volumeof NaCl solution used was calculated according to the
concentration of the Na+ required in the final protein-
[99mTc(CO)3]
+ solution after addition of [99mTc(CO)3]
+
(see Additional file 1 for [Na+] calculations). Final protein
concentrations were 0.85 mg/mL rCR2 (53.1 μM),
0.42 mg/mL α-CD33 scFv (14.5 μM) and α-PSMA scFv
(15.2 μM), and 0.68 mg/mL α-VCAM-1 scFv (23.6 μM).
The labelling reaction was carried out at 37°C and moni-
tored for 2 h with labelling efficiency determined at 5, 15,
30, 60, 90, and 120 min using iTLC-SA paper with citrate
buffer as the mobile phase. This system provided a defini-
tive separation between the [99mTc(CO)3]
+-labelled pep-




− (both with Rf = 1). The large separation between
the peaks enabled the iTLC-SA strips to be cut in half and
both the solvent front and baseline segments analysed
using a gamma counter. Radiolabelling efficiency was
expressed as a ratio of the [99mTc(CO)3]
+ protein-labelled




− (Rf = 1). The influence of pH, protein concen-
tration and reaction temperature was evaluated using
rCR2 and can be found in Additional file 1.
Determining site specificity with a His-tag challenge
A non-His-tagged protein (C2Ac [12]) was allowed to
compete for radiolabel with a His-tagged protein (α-
CD33 scFv) by incubating an equimolar mixture of both
proteins (55 μM:55 μM) in a one-pot radiolabelling reac-
tion using the IsoLink kit method 2 described above. As
controls, the proteins were radiolabelled separately using
55 μM concentrations. The reactions were allowed to in-
cubate for 1 h at 37°C, after which 5 μL samples were
taken from each reaction mixture and loaded onto an
SDS-PAGE gel (12% NuPage gel, Invitrogen, Paisley, PA,
UK). After the gel was run, a reference lane with mo-
lecular weight markers was spotted with radioactivity at
the 15- and 30-kDa bands. After protein separation via
electrophoresis, phosphor screens (Perkin Elmer, Shelton,
CT, USA) were exposed for 10 s, followed by imaging
using a Cyclone® phosphorimager system (Perkin Elmer).
The gel was analysed using ImageJ software (NIH,
Bethesda, MD, USA), and the fraction of total radioactivity
bound to each of C2Ac and α-CD33 scFv was determined
via densitometry of the protein bands.
Results
Reducing the volume of the IsoLink kit increases the
[99mTc(CO)3]
+ concentration while maintaining its
radiochemical purity
Labelling at high protein and [99mTc(CO)3]
+ concentra-
tion is essential to achieve maximum SA and LE within
a suitable timeframe (see Additional file 1: Figure S1)
and to avoid the need for post-labelling purification. In
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from the standard 1 mL (method 1 above) to 350 to
400 μL by adding a more concentrated solution of
[99mTcO4]
−. The radioactivity concentration in typical
clinical generator eluates is easily sufficient to provide
the required activity for clinical scanning in this reduced
volume. We established that a minimum of 350 μL was
required to completely dissolve the kit reagents. Recon-
stituting the standard IsoLink kit with a volume <350 μL
while heating to 100°C led to precipitation and yielded
only 82% ± 2.7% conversion of [99mTcO4]
− to [99mTc(CO)3]
+
(Figure 1d), whereas reconstituting with 350 μL or more
gave no precipitate, a radiochemical yield of >97% ± 1.6%
(Figure 1a) and a radioactivity concentration of approxi-
mately 5 to 6 GBq/mL after neutralisation of the [99mTc
(CO)3]
+ solution to pH 7.4 with 1 M HCl (method 1 re-
sulted in a radioactivity concentration of 2 to 3 MBq/μL).
In method 3, we further reduced the kit volume by subdiv-
iding the kit into 260-μL freeze-dried aliquots, each able
to reduce up to 1 GBq [99mTcO4]
− in 100 μL resulting
in a radioactivity concentration of approximately 8 GBq/
mL after neutralisation. Quality control was carried outFigure 1 TLC quality control of [99mTcO4]
− reduction to [99mTc(CO)3]
+.
arrow) and Rf = 0.2 to 0.8 for [
99mTc(CO)3]
+ (red arrow). (a) Commercial IsoL
350 μL [99mTcO4]− (method 2) and (c) adapted kit with 100 μL [99mTcO4]− (me
(a, b, c) result in >98% radiochemical yield for [99mTc(CO)3]
+ formation, where
formation.comparing the radiochemical purity of [99mTc(CO)3]
+ in
the three kit formulations used. Using TLC, it was dem-
onstrated that yield and purity of [99mTc(CO)3]
+ was the
same (>97%) using methods 1, 2 and 3 (Figure 1a, b, c).
High [Na+] improves specific activity and labelling
efficiency when radiolabelling His-tagged proteins with
[99mTc(CO)3]
+
To evaluate the influence of [Na+] on the LE of His-
tagged proteins with [99mTc(CO)3]
+, four His-tagged
proteins were radiolabelled at controlled [Na+] ranging
from 0.25 to 0.63 M (with 0.44 M being the [Na+] in
1 mL of 0.9% saline [99mTcO4]
−) using [99mTc(CO)3]
+ prep-
aration method 3 above as a basis. We demonstrated
that at given incubation times and temperatures, the
total [Na+] affects SA and LE of the recombinant pro-
teins when radiolabelling with [99mTc(CO)3]
+ (Figure 2,
Tables 1 and 2). To further clarify the correlation be-
tween [Na+] and improved LE, the comparison was
made between the time taken to reach a 50% radiochem-
ical yield for the proteins at the different [Na+]. For the
α-CD33 scFv, α-PSMA scFv and α-VCAM-1 scFv proteins,Rf = 0.9 for [
99mTcO4]
− (green arrow), Rf = 0 for
99mTc colloids (blue
ink kit with 1 mL [99mTcO4]
− (method 1), (b) modified IsoLink kit with
thod 3). (d) Commercial IsoLink kit dissolved with 260 μL [99mTcO4]−. Kits
as kit (d) resulted in 82%± 2.9% radiochemical yield for [99mTc(CO)3]
+
Figure 2 Effect of [Na+] on [99mTc(CO)3]
+ radiolabelling of His-tagged proteins. Labelling efficiencies (n = 3) of (a) rCR2, (b) α-CD33 scFv,
(c) α-PSMA scFv and (d) α-VCAM-1 scFv proteins were determined at 5, 15, 30, 60, 90 and 120 min and represented as a percentage of incorporated
[99mTc(CO)3]
+. Error bars represent the standard deviation of the mean of the triplicate. Where error bars are not visible, they are smaller than the data
points.
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time required to reach a 50% radiochemical yield by at
least 66% (Table 1). The positive correlation between LE
and SA and the [Na+] in the radiolabelling solution is evi-
dent. Furthermore, for the in vivo application of [99mTc
(CO)3]
+:protein bioconjugates, a 95% radiochemical purity
is typically accepted as a threshold for clinical acceptabil-
ity. Often a purification step is required in the process of
producing the radiolabelled proteins (see Additional file 1:
Table S1) to achieve this threshold. Table 2 demonstrates
that increasing the [Na+] to 0.63 M enables the 95% radio-
chemical yield threshold to be reached within a shorter
time (maximum 75 min for the proteins used here), after
which a purification step is not required prior to its
in vivo use. At low salt (0.25 M), a radiochemical yield of
95% is not achievable after 2 h of incubation with [99mTcTable 1 Time taken to reach 50% LE of four His-tagged
proteins at varying [Na+]
His-tagged protein 0.25 M [Na+] 0.44 M [Na+] 0.63 M [Na+]
rCR2 - 34 ± 1.4 min 10.2 ± 0.1 min
α-CD33 scFv 58.5 ± 6.3 min 31.7 ± 3.5 min 19.5 ± 2.4 min
α-PMSA scFv 15.2 ± 3.8 min 4.7 ± 0.8 min 3.9 ± 0.5 min
α-VCAM-1 scFv 65.5 ± 10.5 min 19.9 ± 0.2 min 13.2 ± 2.6 min(CO)3]
+. The rCR2 protein was further analysed at an in-
creased [Na+] of 0.88 M. However, in this instance, there
was no further positive impact on the LE (data not
shown).
Non-specific binding of [99mTc(CO)3]
+ does not occur in
the presence of a His-tag
We and others have previously shown that [99mTc(CO)3]
+
can bind non-specifically with a low labelling efficiency
(approximately 10%) to proteins in the absence of a His-
tag [12,2]. In this study, a competitive binding assay was
developed by co-incubating equimolar amounts of two
proteins, one His-tagged and the other non-His-tagged,
with [99mTc(CO)3]
+. The radiolabel preferentially bound
to the His-tagged protein by a factor of at least 50. Densi-
tometry of the phosphor image indicated >98% ± 1.8% of
[99mTc(CO)3]
+ was bound to the His-tagged protein (α-
CD33 scFv) after 1 h incubation, whereas <2% ± 0.9% was
complexed ‘non-specifically’ to the non-His-tagged pro-
tein C2Ac (Figure 3).
Discussion
Technetium-99 m is well suited for small (<55 kDa)
protein-based tracers (glomerular filtration molecular
weight cutoff approximately 45 kDa below which the
Table 2 Time taken to reach 95% LE of four His-tagged
proteins at varying [Na+]
His-tagged protein 0.25 M [Na+] 0.44 M [Na+] 0.63 M [Na+]
rCR2 - N/A 71.1 ± 3.8 min
α-CD33 scFv N/Aa 106.8 ± 2 min 68.9 ± 1.2 min
α-PMSA scFv N/Ab 51.5 ± 14 min 34.6 ± 6.4 min
α-VCAM-1 scFv N/Ac 110.8 ± 5.1 min 73.2 ± 3.8 min
aLE for α-CD33 scFv at 75 min was approximately 51.3%; bLE for α-PMSA scFv
at 75 min was approximately 65.8%; cLE for α-VCAM-1 scFv at 75 min was
approximately 52.7%.
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Its 6-h half-life is sufficiently long to carry out radiolabel-
ling and allow for slower blood clearance of minutes to
hours as compared to small molecules with seconds to
minutes. Furthermore, 99mTc is readily available at low
cost from transportable 99Mo/99mTc generators and has
favourable photon energy for imaging while minimising
patient radiation-absorbed dose. To radiolabel proteins
with 99mTc, the tricarbonyl method developed by Waibel
et al. [1] offers a convenient solution enabling labelling
without prior modification with bifunctional chelators,
under mild conditions in as little as 60 min, and has re-
cently supported the development of new radiopharma-
ceuticals [12,27].
A number of studies have demonstrated good stability
of [99mTc(CO)3]
+:His-tagged protein complex, with min-
imal transchelation or loss of bound activity, by challen-
ging with high concentrations of histidine and cysteine
or incubating in serum [12,14,16,17]. Our group has re-
cently shown that the complex specifically binds to the
His-tag, demonstrated by the fact that rhenium tricarbo-
nyl labelled His-tag protein post-tryptic digest is only
bound to peptide fragments containing a His-tag [12].
Previous reports have indicated that non-His-tag pro-
teins can be radiolabelled with [99mTc(CO)3]
+ [4] albeit
with relatively low efficiency, but little or no challengeFigure 3 Specificity of [99mTc(CO)3]
+ to His-tagged protein was demo
Non-His-tagged protein (C2Ac, 15 kDa) was co-incubated with His-tagged
then separated using SDS-PAGE, and radiolabelling was visualised using ph
α-CD33 scFv; lanes 2, C2Ac; lanes 3, α-CD33 scFv. Radioactive markers, indicor stability data was reported. By using a competitive
binding assay, here we demonstrated that the technetium
tricarbonyl indeed binds selectively to a His-tagged pro-
tein in the presence of a non-His-tagged protein and little
or no (<2% ± 0.9%) non-specific labelling was observed.
Low radiolabelling efficiency (<95%) of radiopharmaceu-
tical is problematic, with any unlabelled material compet-
ing for target, hampering quantitative measurements and
imaging sensitivity, and requiring an additional purifica-
tion step prior to imaging. High SA enables a radioactive
signal using a low concentration of radiopharmaceutical
well below the pharmacologically active dose and is crucial
for imaging low-concentration targets. Radiolabelling the
recombinant proteins according to the IsoLink instruc-
tions resulted in relatively poor SA and LE due to exces-
sive dilution of the protein (Additional file 1: Figure S1).
As previously reported, we found that protein concen-
tration, pH and temperature play a key role in achieving
maximum SA and LE (Additional file 1: Figure S1) when
labelling with technetium tricarbonyl. Achieving the op-
timal conditions however is currently hampered with the
commercial IsoLink kit. To overcome this, we prepared
modified kits that can produce a [99mTc(CO)3]
+ solution
with radiochemical purity equal to that of the unmodi-
fied kits but with higher radioactivity concentration. The
lower volume means that the radiolabelled product can
conveniently be used for preclinical in vivo studies, mak-
ing more economical use of both protein and radioactiv-
ity. The higher protein and radionuclide concentration
leads to a faster labelling reaction, in turn to achieving
higher SA and LE in the same incubation time, or a
shorter incubation time to reach the same SA and LE.
Importantly, it reduces the incubation time, temperature
and amount of protein needed to reach 95% LE (the
threshold at which radiochemical purity is typically
regarded as adequate for in vivo use) and hence makes it
easier to avoid the need for post-labelling purificationnstrated via (a) SDS-PAGE followed by (b) phosphor imaging.
protein (α-CD33 scFv, 29 kDa) and [99mTc(CO)3]+. The proteins were
osphor imaging. Lanes M, molecular weight marker; lanes 1, C2Ac +
ated by black arrows, were placed at 2.5, 15, 30 and 110 kDa.
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versible binding to columns and filters.
We also found that total [Na+] in the reaction mix-
ture affects SA and LE, and this effect can be exploited
by increasing [Na+] to increase the rate at which max-
imum SA and 95% LE are reached by up to fourfold.
IsoLink kits contain a significant amount of Na+,
0.31 mmol, and the [Na+] of the final protein: [99mTc
(CO)3]
+ reaction mixture is dependent on the volume
of the [99mTc(CO)3]
+ solution added (see Additional file 1
for [Na+] calculations).
Using the conventional IsoLink kit, rates of labelling
reactions and times to reach maximum SA and LE vary
between proteins. These variations may be due to His-
tag accessibility in the protein's tertiary structure or a
charge effect from adjacent amino acids interacting with
the positively charged tricarbonyl core. Increasing the
ionic strength or [Na+] in the reaction mixture may
contribute to a kinetically favourable binding environ-
ment. For example, at pH 7.5, one would expect one or
more of the histidines in the His-tag to be positively
charged and if, as reported in the literature, the techne-
tium tricarbonyl precursor is also positively charged, the
increase in the ionic strength of the buffer may dissipate
the ionic repulsion between the species thus lowering
the activation energy of binding.
Conclusions
In conclusion, the standard IsoLink kit, while reliably pro-
ducing the technetium tricarbonyl precursor in high yield,
is not optimal in scale for the routine and economic radi-
olabelling of different His-tag recombinant proteins at
high specific activity for in vivo use. Each protein will
need optimisation to achieve optimal SA and LE, and in
some cases, adequate SA and LE may not be reached for
routine clinical or preclinical use and purification steps
are then required. By introducing modifications to the kit,
it is possible to achieve reproducible and robust radiola-
belling with optimal SA and LE in shorter incubation
times and with smaller quantities of protein, avoid post-
labelling purification steps and make the most efficient
use of both protein and 99mTc, improving the prospects
for clinical translation and commercialisation of the tri-
carbonyl kit.Additional file
Additional file 1: Supporting information. Here, we provide a
tabulated literature review summarising labelling conditions and
outcomes of His-tagged proteins radiolabelled with 99mTc-tricarbonyl
(Additional file 1: Table S1). Additionally, we describe the effect of varying
conditions (pH, temperature and protein concentration) when labelling a
His-tagged protein with the IsoLink kit (Additional file 1: Figure S1). Finally,
the calculation steps we used to calculate the [Na+] throughout this paper
are outlined.Abbreviations
LE: labelling efficiency; SA: specific activity.
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